Eteplirsen
Eteplirsen (brand name Exondys 51) is a medication to treat, but not cure, some types of Duchenne muscular dystrophy (DMD), caused by a specific mutation. Eteplirsen only targets specific mutations and can be used to treat about 14% of DMD cases. Eteplirsen is a form of antisense therapy.
Clinical data | |
---|---|
Trade names | Exondys 51 |
Other names | AVI-4658 |
License data |
|
Routes of administration | Intravenous infusion |
Drug class | Antisense oligonucleotide |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C364H569N177O122P30 |
Molar mass | 10305.886 g·mol−1 |
SMILES
| |
|
Eteplirsen was developed by Steve Wilton, Sue Fletcher and colleagues at the University of Western Australia and commercialized by Sarepta Therapeutics. After a controversial debate surrounding the drug's efficacy, during which two FDA review panel members resigned in protest, eteplirsen received accelerated approval from the US Food and Drug administration in late 2016. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) refused to authorize the use of eteplirsen.